Overview

The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori

Status:
Not yet recruiting

Trial end date:
2022-12-31

Target enrollment:
0

Participant gender:
All

Summary

The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. The aim of this prospective study is to investigate the efficacy of Triple Therapy with Vonoprazan, Amoxicillin, and Bismuth for eradication of Hp, compared with standard quadruple therapy.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Huazhong University of Science and Technology

Treatments:

Amoxicillin
Bismuth
Clarithromycin
Esomeprazole
Potassium Citrate

Criteria

Inclusion Criteria:

- Helicobacter pylori infected patients comfirmed by 13C/14C UBT

- age 18~65

Exclusion Criteria:

- prior Hp eradication therapy including amoxicillin and clarithromycin

- previous gastric resection

- allergic to the drugs used in this study

- previous use of proton pump inhibitors, bismuth, H2 receptor antagonist or
antibiotics, probiotics within 4 weeks of the study

- Patients who were pregnant or lactating

- Patients taking NSAIDs, alcoholic or with other serious disease (e.g. hepatopathy,
heart disease, nephropathy#diabete mellitus, hypertension…) effect the evaluation of
this study

- Can't express the complaint correctly